drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (Biological; TCR-T cells)
drug_description
Patient-derived T cells genetically engineered to express a T-cell receptor recognizing the TP53 R248Q mutant peptide presented by HLA-A*11:01; reinfused to mediate antigen-specific cytotoxicity against TP53 R248Q–positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express an HLA-A*11:01–restricted T-cell receptor that recognizes the TP53 R248Q mutant peptide on MHC class I. Upon binding the mutant peptide–MHC complex on tumor cells, the T cells activate TCR signaling and mediate antigen-specific cytotoxicity via perforin/granzyme release and cytokine-driven killing, selectively targeting TP53 R248Q–positive cancer cells.
drug_name
Autologous TP53 R248Q-specific TCR-engineered T cells (HLA-A*11:01–restricted)
nct_id_drug_ref
NCT06619886